- Disperse 5 tablets or less in 50 mL of non-carbonated water and mix well. Mixture should be white to almost white with visible particles expected.
- Administer through the feeding tube immediately.
- Repeat with additional tablets until desired dose is reached.
- Rinse and flush with 25 mL of additional water to ensure no tablet residue is left in materials used for preparation or the feeding tube.
- Administer with food.
CYP3A4 Inducers
Coadministration of SIRTURO with a moderate or strong CYP3A4 inducer decreases the systemic exposure of bedaquiline and may reduce the therapeutic effect of SIRTURO. Avoid coadministration of SIRTURO with moderate or strong CYP3A4 inducers, such as efavirenz and rifamycins (i.e., rifampin, rifapentine and rifabutin)
[see
Drug Interactions (7.1)]
.
CYP3A4 Inhibitors
Coadministration of SIRTURO with CYP3A4 inhibitors increases the systemic exposure of bedaquiline, which may increase the risk of adverse reactions. Closely monitor patient safety (e.g., liver function) when SIRTURO is coadministered with CYP3A4 inhibitors
[see
Drug Interactions (7.1)]
.
Clinical Studies Experience in Adults
Adverse reactions for SIRTURO were identified from safety data from 335 patients who received SIRTURO for eight weeks (Study 2) and 24 weeks (Studies 1 and 3), and 354 patients who received SIRTURO for 40 weeks or 28 weeks (Study 4). In these studies, patients received SIRTURO in combination with other antimycobacterial drugs.
Studies 1 and 2 were randomized, double-blind, placebo-controlled trials in newly diagnosed patients with pulmonary TB due to
M. tuberculosis resistant to at least rifampin and isoniazid. Study 3 was an open-label, noncomparative study with SIRTURO administered as part of an individualized treatment regimen in previously treated patients with pulmonary TB due to
M. tuberculosis resistant to at least rifampin and isoniazid, including patients resistant to second-line injectables and/or fluroquinolones.
In Study 1, 35% were Black, 17% were Hispanic, 13% were White, 9% were Asian, and 26% were of another race. Eight of 79 (10%) patients in the SIRTURO group and 16 of 81 (20%) patients in the placebo treatment group were HIV infected. Seven (8.9%) SIRTURO-treated patients and six (7.4%) placebo-treated patients discontinued Study 1 because of an adverse reaction.
Study 4 was an open-label, randomized, active-controlled trial in patients with pulmonary TB due to
M. tuberculosis resistant to at least rifampin that evaluated a 40-week arm of SIRTURO in combination with other oral antimycobacterial drugs compared with a 40-week active control arm that included an injectable antimycobacterial drug in combination with other oral antimycobacterial drugs. A 28-week arm including SIRTURO, an injectable and other antimycobacterial drugs, was also evaluated in the trial, but recruitment was stopped early due to changes in the standard of care. In the population treated in the two 40-week arms (N=413), the median age was 32.8 years, 61% were male, 46% were Asian, 36% were Black, 18% were White and 16% were HIV infected.
Common Adverse Reactions
Table 3 presents select adverse reactions that occurred more frequently in the SIRTURO arm than the placebo arm in Study 1. The most common adverse reactions reported in 10% or more patients treated with SIRTURO and occurred more frequently than the placebo arm were nausea, arthralgia, headache, hemoptysis and chest pain.
Table 3: Select Adverse Reactions from Study 1 that Occurred More Frequently than Placebo During Treatment with SIRTURO| Adverse Reactions | SIRTURO Treatment Group
N=79
n (%)
| Placebo Treatment Group
N=81
n (%)
|
|---|
| Nausea | 30 (38) | 26 (32) |
| Arthralgia | 26 (33) | 18 (22) |
| Headache | 22 (28) | 10 (12) |
| Hemoptysis | 14 (18) | 9 (11) |
| Chest Pain | 9 (11) | 6 (7) |
| Anorexia | 7 (9) | 3 (4) |
| Transaminases Increased
Terms represented by 'transaminases increased' included transaminases increased, AST increased, ALT increased, hepatic enzyme increased, and hepatic function abnormal. | 7 (9) | 1 (1) |
| Rash | 6 (8) | 3 (4) |
| Blood Amylase Increased | 2 (3) | 1 (1) |
No additional unique adverse reactions were identified from the uncontrolled Study 3.
Transaminase Elevations
In both Studies 1 and 2, transaminase elevations of at least 3 times the upper limit of normal developed more frequently in the SIRTURO treatment group (11/102 [10.8%] vs 6/105 [5.7%]) than in the placebo treatment group. In Study 3, 22/230 (9.6%) patients had alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal during the overall treatment period.
In Study 4 during the treatment phase, transaminase elevations of at least 3 times the upper limit of normal developed in 45/211 (21%) in the 40-week SIRTURO treatment group, 45/202 (22%) in the 40-week active comparator group, and 23 /143 (16%) in the 28-week SIRTURO-containing group.
Table 4 presents select adverse reactions occurring in 5% or greater of patients receiving SIRTURO in combination with other antimycobacterial drugs in the 40-week SIRTURO arm in Study 4. The most common adverse reactions reported in 10% or more patients in the 40-week SIRTURO arm were QTc prolongation, nausea, vomiting, arthralgia, transaminases increased, abdominal pain, pruritus, dizziness, headache, chest pain, rash, insomnia, dry skin, and palpitations.
Table 4: Select Adverse Reactions Occurring in 5% or Greater of Patients Receiving the 40-Week SIRTURO Regimen in Study 4| Adverse Reactions | SIRTURO
40-week, bedaquiline, levofloxacin, clofazimine, ethambutol, and pyrazinamide, supplemented by high-dose isoniazid and prothionamide in the first 16 weeks (intensive phase). N=211
n (%)
| Active Control
40-week control treatment of moxifloxacin or levofloxacin, clofazimine, ethambutol, pyrazinamide, supplemented by injectable kanamycin, high dose isoniazid and prothionamide in the first 16 weeks (intensive phase). ,Study 4 was not designed to evaluate meaningful comparisons of the incidence of adverse reactions in the SIRTURO and the active control treatment groups. N=202
n (%)
|
|---|
| QTc prolongation | 128 (61) | 113 (56) |
| Nausea | 114 (54) | 126 (62) |
| Vomiting | 112 (53) | 125 (62) |
| Arthralgia | 93 (44) | 67 (33) |
| Transaminases increased
Terms represented by 'transaminases increased' included AST increased, ALT increased, hepatic enzyme increased, hepatic function abnormal, hypertransaminasemia, and transaminases increased. | 63 (30) | 59 (29) |
| Abdominal pain
Terms represented by 'abdominal pain' included abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal tenderness. | 60 (28) | 48 (24) |
| Pruritus
Terms represented by 'pruritus' included pruritus, pruritus generalized, and rash pruritic. | 58 (27) | 44 (22) |
| Dizziness | 37 (18) | 42 (21) |
| Headache | 36 (17) | 36 (18) |
| Chest pain | 33 (16) | 24 (12) |
| Rash
Terms represented by 'rash' included rash, rash papular and rash maculopapular. | 30 (14) | 17 (8) |
| Insomnia | 30 (14) | 19 (9) |
| Dry skin | 25 (12) | 16 (8) |
| Palpitations | 21 (10) | 13 (6) |
| Myalgia | 19 (9) | 6 (3) |
| Paresthesia | 16 (8) | 8 (4) |
| Diarrhea | 12 (6) | 17 (8) |
In the 28-week SIRTURO-containing arm (N=143), in which SIRTURO was used in combination with other antimycobacterial drugs, the most common selected adverse reactions (greater than 10%) were QTc prolongation (56%), arthralgia (55%), nausea (43%), vomiting (29%), pruritus (25%), transaminases increased (21%), dizziness (21%), chest pain (17%), abdominal pain (17%), headache (16%), rash (12%), and hemoptysis (11%).
Mortality Imbalance in Clinical Studies
In Study 1, there was a statistically significant increased mortality risk by Week 120 in the SIRTURO treatment group compared to the placebo treatment group (9/79 (11.4%) versus 2/81 (2.5%), p-value=0.03, an exact 95% confidence interval of the difference [1.1%, 18.2%]). Five of the 9 SIRTURO deaths and the 2 placebo deaths were TB-related. One death occurred during the 24-week SIRTURO treatment period. The median time to death for the remaining eight patients in the SIRTURO treatment group was 329 days after last intake of SIRTURO. The imbalance in deaths is unexplained; no discernible pattern between death and sputum conversion, relapse, sensitivity to other drugs used to treat TB, HIV status, and severity of disease was observed.
In the open-label Study 3, 16/233 (6.9%) patients died. The most common cause of death as reported by the investigator was TB (nine patients).
In Study 4, patients originally assigned to non-SIRTURO containing regimens could receive SIRTURO as salvage when the original therapy was not tolerated or ineffective. At Week 132, deaths were observed in 11/211 (5.2%) patients in the 40-week SIRTURO arm versus 8/202 (4.0%) patients in the 40-week active control arm. For the 40-week SIRTURO arm, the most common cause of death was related to TB (five patients). In the 40-week active control arm, which included four of 29 patients who received SIRTURO as part of a salvage treatment, the most common cause of death was related to respiratory disease (e.g., TB, lobar pneumonia, respiratory distress in an HIV-positive patient). The adjusted difference in proportion of fatal adverse reactions between the 40-week SIRTURO arm and the 40-week active control arm was 1.2% [95% CI (-2.8%; 5.2%)]. In the 28-week SIRTURO arm at Week 132, 2/143 (1.4%) patients died; one of the two deaths was also related to TB. The overall mortality for patients treated with SIRTURO was 17/383 (4.4%).
Clinical Studies Experience in Pediatric Patients
The safety assessment of SIRTURO in pediatric patients is based on data from 45 pediatric patients in an ongoing, single-arm, open-label, multi-cohort trial.
Pediatric Patients (12 years to less than 18 years of age)
The first cohort was designed to enroll patients 12 years to less than 18 years of age (fifteen patients 14 years to less than 18 years of age were enrolled) with confirmed or probable pulmonary TB due to
M. tuberculosis resistant to at least rifampin who received SIRTURO (400 mg once daily for the first 2 weeks and 200 mg 3 times per week for the following 22 weeks) in combination with a background regimen
[see
Clinical Studies (14.2)]
.
The most common adverse reactions were arthralgia in 6/15 (40%) patients, nausea in 2/15 (13%) patients, and abdominal pain in 2/15 (13%) patients. Among the 15 patients, no deaths were reported during the study (Week 120 analysis). Observed laboratory abnormalities were comparable to those in adults.
Pediatric Patients (5 years to less than 12 years of age)
The second cohort was designed to enroll patients 5 years to less than 12 years of age (fifteen patients aged 5 years to less than 11 years of age were enrolled) with confirmed or probable pulmonary TB due to
M. tuberculosis resistant to at least rifampin who received SIRTURO (200 mg once daily for the first 2 weeks and 100 mg 3 times per week for the following 22 weeks) in combination with a background regimen
[see
Clinical Studies (14.2)]
.
The most common adverse reactions were related to elevations in liver enzymes (5/15, 33%), and led to discontinuation of SIRTURO in three patients. Elevations in liver enzymes were reversible upon discontinuation of SIRTURO and some of the background regimen drugs. Among these 15 pediatric patients, no deaths were reported during the study (Week 120 analysis).
Pediatric Patients (2 years to less than 5 years of age)
The third cohort enrolled 15 patients aged 2 years to less than 5 years of age with confirmed or probable pulmonary TB due to
M. tuberculosis resistant to at least rifampin who received SIRTURO (80 to 120 mg once daily for the first 2 weeks and 40 to 60 mg 3 times per week for the following 22 weeks based on weight), in combination with a background regimen
[see
Clinical Studies (14.2)]
.
The most common adverse reaction was vomiting in 3/15 (20%) patients. Among these 15 pediatric patients, no deaths were reported during treatment with SIRTURO (Week 24 analysis).
Strong and Moderate CYP3A4 Inducers
Coadministration of SIRTURO with moderate or strong CYP3A4 inducers may decrease systemic exposure of bedaquiline. Avoid coadministration of SIRTURO with strong or moderate CYP3A4 inducers
[see
Clinical Pharmacology (12.3)]
.
CYP3A4 Inhibitors
Coadministration of SIRTURO with CYP3A4 inhibitors increases the systemic exposure of bedaquiline which may increase the risk of adverse reactions. Closely monitor patient safety (e.g., liver function) when SIRTURO is coadministered with CYP3A4 inhibitors. No dose adjustment of SIRTURO is needed when coadministered with CYP3A4 inhibitors
[see
Clinical Pharmacology (12.3)]
.
Risk Summary
Available data from published literature of SIRTURO use in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks associated with active TB during pregnancy
(see
Clinical Considerations)
.
Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the fetus due to oral administration of bedaquiline to pregnant rats and rabbits during organogenesis at exposures up to 6 times the clinical dose based on AUC comparisons
(see
Data)
.
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-Associated Maternal and/or Embryo/Fetal Risk
Active TB in pregnancy is associated with adverse maternal and neonatal outcomes including maternal anemia, caesarean delivery, preterm birth, low birth weight, birth asphyxia, and perinatal infant death.
Data
Animal Data
Pregnant rats were treated with bedaquiline at 5, 15 and 45 mg/kg (approximately 0.7, 2 and 6 times the clinical dose based on AUC comparisons) during the period of organogenesis (gestational Days 6 to 17, inclusive). Pregnant rabbits were treated with bedaquiline at 10, 30 and 100 mg/kg (approximately 0.05, 0.2 and 1.5 times the clinical dose based on AUC comparisons) during the period of organogenesis (gestational Days 6 to 19, inclusive). No embryotoxic effects were found in rats or rabbits at dose exposures up to 6 times the clinical dose exposures based on AUC comparisons.
Risk Summary
Data from a published clinical lactation study demonstrate higher bedaquiline concentrations in breast milk compared to maternal plasma, suggesting that bedaquiline accumulates in breast milk
(see
Data)
. Data are insufficient to determine effects of the drug on the breastfed infants. No data are available on the effects of the drug on milk production. Because of the potential for serious adverse reactions in a breastfed infant, including hepatotoxicity, advise patients that breastfeeding is not recommended during treatment with SIRTURO and for 27.5 months (5 times the half-life) after the last dose unless infant formula is not available.
Clinical Considerations
If an infant is exposed to bedaquiline through breast milk, monitor for signs of bedaquiline-related adverse reactions, such as hepatotoxicity
[see
Adverse Reactions (6)].
Data
A clinical lactation study was conducted in two lactating women who were approximately 7 weeks' postpartum. Bedaquiline and M2, its active metabolite, levels were measured between approximately 27 and 48 hours after the last bedaquiline dose, and concentrations of bedaquiline and M2 ranged from 2.61 to 8.11 mg/L and 0.27 to 0.81 mg/L, respectively. The milk:plasma ratios for bedaquiline and M2 at 27 to 48 hours after the last dose of bedaquiline ranged from approximately 19 to 29 and 4 to 6, respectively.
Cardiac Electrophysiology
In Study 1, the largest mean increase in QTc during the 24 weeks of SIRTURO treatment was 16 ms compared to 6 ms with placebo treatment (at Week 18). After SIRTURO treatment ended, the QTc gradually decreased, and the mean value was similar to that in the placebo group by study Week 60.
In Study 4, the mean change from baseline in QTc for the SIRTURO-containing arm was 22 ms (95% CI: 19; 24) at Week 2 (i.e., the end of the 2-week SIRTURO loading period), and 8 ms (95% CI: 2; 13) in the levofloxacin-containing control arm subgroup.
In Study 4, the mean QTc increased from baseline over the first 12 weeks for both SIRTURO and the non-SIRTURO containing control arm, when a plateau was reached. The largest mean QTc increase from baseline was 35 ms (95% CI: 32 to 38 ms) for the SIRTURO-containing arm and 28 ms (95% CI: 21 to 34 ms) for the levofloxacin-containing control arm subgroup
[see
Warnings and Precautions (5.1)and
Drug Interactions (7.3)].
Pharmacokinetics (PK) parameters
The pharmacokinetic properties of bedaquiline are summarized in Table 5 as mean (SD) in adult patients.
Table 5: Model-Derived Pharmacokinetic Parameters of Bedaquiline and M2 (mean [SD]) after Multiple Doses of SIRTURO at the Recommended Dosing Regimen| Pharmacokinetic Parameters | Bedaquiline |
|---|
| SD=Standard Deviation |
| Absorption | |
| Food effect | High fat meal (22 grams of fat, 558 total Kcal) increased C
max and AUC by 2-fold. SIRTURO should be taken with food to enhance its oral bioavailability.
|
| T
max | Around 5 hours after single oral dose administration of SIRTURO |
| C
max of bedaquiline
| Week 2: 3060 (1124) ng/mL
Week 24: 1838 (684) ng/mL
Week 40: 1787 (666) ng/mL
|
| C
max of M2
| Week 2: 326 (135) ng/mL
Week 24: 234 (85) ng/mL
Week 40: 246 (103) ng/mL
|
| Exposure | |
AUC
168h of bedaquiline
(AUC
24h for Week 2)
| Week 2: 41510 (15064) ng.h/mL
Week 24: 163924 (55710) (ng.h/mL)
Week 40: 168376 (74476) ng.h/mL
|
AUC
168h of M2
(AUC
24h for Week 2)
| Week 2: 7267 (3029) ng.h/mL
Week 24: 37255 (13998) ng.h/mL
Week 40: 39540 (17220) ng.h/mL
|
| Distribution | |
| Percent bound to human plasma protein | greater than 99.9%. |
| apparent central volume of distribution | approximately 117 Liters. |
| Proportionality | C
max and AUC increased proportionally up 700 mg (1.75 times the 400 mg loading dose).
|
| Elimination | After reaching C
max, bedaquiline concentrations decline tri-exponentially.
|
| Apparent clearance of bedaquiline | 2.62 L/h |
| Apparent clearance of M2 | 4.95 L/h |
| Terminal half-life | ~ 5.5 months for both bedaquiline and
Nmonodesmethyl metabolite (M2)
|
| Metabolism | Metabolized to the M2 by CYP3A4; Relative exposure M2 versus bedaquiline: 23%~31% |
| Excretion | |
| Major route of excretion | Fecal excretion is the major route of elimination |
| %Excreted unchanged in urine | less than or equal to 0.001% of the dose in clinical studies |
Specific Populations
Patients with Hepatic Impairment: After single-dose administration of 400 mg SIRTURO to 8 adult patients with moderate hepatic impairment (Child-Pugh B), mean exposure to bedaquiline and M2 (AUC
672h) was approximately 20% lower compared to healthy adults. SIRTURO has not been studied in patients with severe hepatic impairment
[see
Warnings and Precautions (5.4)and
Use in Specific Populations (8.6)].
Patients with Renal Impairment:SIRTURO has mainly been studied in adult patients with normal renal function. Renal excretion of unchanged bedaquiline is not substantial (less than or equal to 0.001%).
In a population pharmacokinetic analysis of adult TB patients treated with SIRTURO 200 mg three times per week, creatinine clearance was not found to influence the pharmacokinetic parameters of bedaquiline. It is therefore not expected that mild or moderate renal impairment will have a clinically relevant effect on the exposure to bedaquiline. However, in patients with severe renal impairment or end-stage renal disease requiring hemodialysis or peritoneal dialysis bedaquiline concentrations may be increased due to alteration of drug absorption, distribution, and metabolism secondary to renal dysfunction. As bedaquiline is highly bound to plasma proteins, it is unlikely that it will be significantly removed from plasma by hemodialysis or peritoneal dialysis
[see
Use in Specific Populations (8.7)]
.
Male and Female Patients: In a population pharmacokinetic analysis of adult TB patients treated with SIRTURO no clinically relevant difference in exposure between men and women were observed.
Race or Ethnicity: In a population pharmacokinetic analysis of adult TB patients treated with SIRTURO, systemic exposure (AUC) to bedaquiline was found to be 34% lower in Black patients than in patients from other race categories. This lower bedaquiline exposure in Black patients was not associated with lower efficacy in clinical trials.
HIV Coinfection: Bedaquiline exposure in patients coinfected with HIV was similar to that of patients not infected with HIV.
Geriatric Patients: There are limited data on the use of SIRTURO in TB patients 65 years of age and older.
In a population pharmacokinetic analysis of adult TB patients treated with SIRTURO, age was not found to influence the pharmacokinetics of bedaquiline. In five patients 65 to 69 years of age, the systemic bedaquiline exposure was similar to that in other adults.
Pediatric Patients:
Pediatric patients 12 years to less than 18 years of age with TB due to M. tuberculosis resistant to at least rifampin
The pharmacokinetic parameters of bedaquiline in 15 pediatric patients (body weight at baseline: 38 to 75 kg) who received the same adult dosage regimen of SIRTURO (400 mg once daily for the first two weeks and 200 mg three times per week for the following 22 weeks) in combination with a background regimen were comparable to those in adults. There was no impact of body weight on bedaquiline pharmacokinetics in this cohort.
Pediatric patients 5 years to less than 12 years of age with TB due to M. tuberculosis resistant to at least rifampin
Fifteen pediatric patients (body weight at baseline: 14 to 36 kg) received SIRTURO (200 mg once daily for the first two weeks and 100 mg three times per week for the following 22 weeks) in combination with a background regimen. Of these 15 pediatric patients, complete pharmacokinetic data were obtained for 10 patients at the aforementioned dosage regimen of SIRTURO. In nine of these 10 pediatric patients who weighed at least 15 kg at baseline, the mean bedaquiline C
max and AUC
24h were similar to those of adult patients receiving the recommended adult dosage regimen. In one of these 10 pediatric patients who weighed 14 kg at baseline, the bedaquiline mean C
max and AUC
24h were 3.8-fold and 2.6-fold, respectively, higher than the mean C
max and AUC
24h in adult patients administered the recommended adult dosage regimen. The clinical significance of this higher pharmacokinetic plasma exposure in this one pediatric patient is not known.
Pediatric patients 2 years to less than 5 years of age with TB due to M. tuberculosis resistant to at least rifampin
Fifteen pediatric patients (body weight at baseline: 10 to 16 kg) received SIRTURO at a dose of 8 mg/kg once daily for 2 weeks (dose range: 80 to 120 mg; not an approved dosing regimen) followed by 4 mg/kg three times per week (dose range: 40 to 60 mg; not an approved dosing regimen) in combination with a background regimen. The results showed that the pediatric patients receiving the dosing regimens used in this pediatric study had mean bedaquiline C
max and AUC
24h comparable to those of adult patients receiving the recommended adult dosage regimen
[see
Use in Specific Populations (8.4)]
.
The recommended dosing regimens for pediatric patients weighing 8 kg to less than 15 kg differ from those used in the pediatric clinical study. For pediatric patients weighing 8 kg to less than 15 kg, the recommended dosing regimens
[see
Dosage and Administration (2.4)]
were determined using a pharmacokinetic modeling and simulation approach based on clinical pharmacokinetic data, to achieve exposures comparable to those observed in adults taking SIRTURO tablets
[see
Use in Specific Populations (8.4)]
.
See
Table 6for a summary of the pharmacokinetic parameters at Week 12 in pediatric patients 2 years to less than 18 years of age.
Table 6: Pharmacokinetic Parameters of Bedaquiline Following Repeat Dose Administration of SIRTURO to Pediatric Patients 2 to Less than 18 Years of Age at Week 12 Administered with Food| Pharmacokinetic Parameter | Bedaquiline
Mean (SD)
|
|---|
| 14 years to less than 18 years
(N=15)
| 5 years to less than 12 years
(N=10)
| 2 years to less than 5 years
(N=15)
|
|---|
| SD=Standard Deviation |
| AUC
24h(ng∙h/mL)
| 26,300 (10,300) | 32,200 (16,300) | 26,700 (7,270)
N=10 |
| C
max(ng/mL)
| 1,800 (736) | 2,430 (1,670) | 1,810 (872) |
| T
max(h)
Median (range) | 4 (2 to 8) | 4 (2 to 8) | 6 (2 to 24) |
| C
min(ng/mL)
| 544 (263) | 461 (173) | 486 (161) |
Drug Interactions Studies
In vitro, bedaquiline did not significantly inhibit the activity of the following CYP450 enzymes that were tested: CYP1A2, CYP2A6, CYP2C8/9/10, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A4/5 and CYP4A, and it does not induce CYP1A2, CYP2C9, CYP2C19, or CYP3A4 activities.
Bedaquiline is an in vitro substrate of CYP3A4, and because of this, the following clinical drug interaction studies were performed.
Clinical Studies
Ketoconazole:Coadministration of multiple-dose bedaquiline (400 mg once daily for 14 days) and multiple-dose ketoconazole (once daily 400 mg for 4 days) in healthy adult subjects increased the AUC
24h, C
maxand C
minof bedaquiline by 22% [90% CI (12; 32)], 9% [90% CI (-2, 21)] and 33% [90% CI (24, 43)] respectively
[see
Drug Interactions (7.1)and
(7.3)]
.
Clarithromycin:Coadministration of a single 100 mg dose of SIRTURO with clarithromycin at steady-state in healthy adults increased the mean [90% CI] bedaquiline exposure AUC
240hby 14% [9%;19%].
Clofazimine:In Study 3, long-term coadministration of clofazimine and SIRTURO, as part of a combination therapy for up to 24 weeks, did not affect bedaquiline exposure.
Rifampin:In a drug interaction study of single-dose 300 mg bedaquiline and multiple-dose rifampin (once daily 600 mg for 21 days) in healthy adult subjects, the exposure (AUC) to bedaquiline was reduced by 52% [90% CI (-57; -46)]
[see
Drug Interactions (7.1)]
.
Antimicrobial agents:The combination of multiple-dose bedaquiline 400 mg once daily with multiple-dose isoniazid/pyrazinamide (300 mg/2000 mg once daily) in healthy adult subjects did not result in clinically relevant changes in the exposure (AUC) to bedaquiline, isoniazid or pyrazinamide
[see
Drug Interactions (7.2)]
.
In a placebo-controlled study in adult patients with, no major impact of coadministration of bedaquiline on the pharmacokinetics of ethambutol, kanamycin, pyrazinamide, ofloxacin or cycloserine was observed.
Lopinavir/ritonavir:In a drug interaction study in healthy adults of single-dose bedaquiline (400 mg) and multiple-dose lopinavir (400 mg)/ritonavir (100 mg) given twice daily for 24 days, the mean AUC of bedaquiline was increased by 22% [90% CI (11; 34)] while the mean C
maxwas not substantially affected. In Study 4, coadministration of SIRTURO with lopinavir/ritonavir in patients coinfected with HIV increased bedaquiline exposure, with an estimated 68% [90% CI (29%; 117%)] increase in mean AUC
168hat Week 24 and 72% [90% CI (32%; 123%)] at Week 40, in HIV-positive Black patients treated with lopinavir/ritonavir (N=16) compared to HIV-positive and -negative Black patients without lopinavir/ritonavir (N=67) treatment
[see
Drug Interactions (7.1)]
.
Nevirapine:Coadministration of multiple-dose nevirapine 200 mg twice daily for 4 weeks in HIV-infected adult patients with a single 400 mg dose of bedaquiline did not result in clinically relevant changes in the exposure to bedaquiline. In Study 4, coadministration of nevirapine and SIRTURO as part of combination therapy for up to 40 weeks in patients coinfected with HIV, resulted in a 29% [90% CI (0; 50%)] decrease in bedaquiline exposure (AUC
168h).
Efavirenz:Coadministration of a single dose of bedaquiline 400 mg and efavirenz 600 mg daily for 27 days to healthy adult volunteers resulted in approximately a 20% decrease in the AUC
infof bedaquiline; the C
maxof bedaquiline was not altered. The AUC and C
maxof the primary metabolite of bedaquiline (M2) were increased by 70% and 80%, respectively. The effect of efavirenz on the pharmacokinetics of bedaquiline and M2 following steady-state administration of bedaquiline has not been evaluated
[see
Drug Interactions (7.3)]
.
Mechanism of Action
SIRTURO is a diarylquinoline antimycobacterial drug that inhibits mycobacterial ATP (adenosine 5'- triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the generation of energy in
M. tuberculosis.
Resistance
A potential for development of resistance to bedaquiline in
M. tuberculosis exists. Modification of the
atpE target gene, and/or upregulation of the MmpS5-MmpL5 efflux pump (
Rv0678 mutations) have been associated with increased bedaquiline MIC values in isolates of
M. tuberculosis. Target-based mutations generated in preclinical studies lead to 8- to 133-fold increases in bedaquiline MIC, resulting in MICs ranging from 0.25 to 4 micrograms per mL. Efflux-based mutations have been seen in preclinical and clinical isolates. These lead to 2- to 8-fold increases in bedaquiline MICs, resulting in bedaquiline MICs ranging from 0.25 to 0.5 micrograms per mL.
M. tuberculosis isolates that had developed at least a 4-fold increase in bedaquiline MIC were associated with mutations in
Rv0678 gene that lead to upregulation of the MmpS5-MmpL5 efflux pump. Isolates with these efflux-based mutations are less susceptible to clofazimine. Isolates that are phenotypically resistant to bedaquiline should be tested for cross-resistance to clofazimine, if clofazimine is being considered as part of the treatment regimen. In Studies 2, 3 and 4 there was no clear relationship between the presence of
Rv0678 mutations at baseline and treatment outcome.
Antimicrobial Activity
SIRTURO has been shown to be active in vitro and in clinical infections against most isolates of
M. tuberculosis [see
Indications and Usage (1)and
Clinical Studies (14)]
.
Susceptibility Testing
MICs for baseline
M. tuberculosis isolates from patients in Studies 1 and 3 and their sputum culture conversion rates at Week 24 and from patients in the 40-week SIRTURO arm of Study 4 at Week 76 are shown in Table 7 below. Based on the available data, there was no relationship between poor microbiologic outcomes and baseline bedaquiline MIC.
Table 7: Culture Conversion Rates in SIRTURO Treatment Groups at Week 24 (Study 1 and 3) and at Week 76 (Study 4), by Baseline Bedaquiline MIC (mITT population)
7H11 agar. Patients who prematurely discontinued were categorized as culture converted (or not) based on the available data. All available data were utilized regardless of changes in treatment.
Baseline Bedaquiline MIC
(micrograms/mL)
| SIRTURO Treatment Group 24-Week Culture Conversion Rate
(Study 1 and Study 3)
n/N (%)
| SIRTURO Treatment Group 76-Week Culture Conversion Rate
(Study 4, 40-Week Arm)
In addition, at Week 76 in the 40-week SIRTURO arm, there were 6 patients for whom no baseline MIC data were available. All 6 patients culture converted.
n/N (%)
|
|---|
| |
|---|
| N=number of patients with data per baseline BDQ MIC category; n=number of patients with culture conversion; MIC=minimum inhibitory concentration |
| ≤ 0.008 | 2/2 (100) | 5/5 (100) |
| 0.015 | 13/15 (86.7) | 26/26 (100) |
| 0.03 | 36/46 (78.3) | 67/69 (97.1) |
| 0.06 | 82/107 (76.6) | 51/51 (100) |
| 0.12 | 36/42 (85.7) | 20/20 (100) |
| 0.25 | 3/4 (75.0) | 2/2 (100) |
| 0.5 | 5/6 (83.3) | 0 |
| ≥ 1 | 0/1 (0) | 0 |
Nineteen patients in the efficacy population of Study 3 had bedaquiline susceptibility testing results of paired (baseline and post-baseline, all of which were at Week 24 or later) genotypically identical
M. tuberculosis isolates. Twelve of the 19 had a post-baseline ≥4-fold increase in bedaquiline MIC. Whole genome sequencing of nine of these 12 post-baseline isolates was done and no mutations were found in the ATP synthase operon. All nine were found to have a mutation in
Rv0678. Eleven of the twelve (11/12) increases in bedaquiline MIC were seen in patients with isolates that also demonstrated increased MICs to fluoroquinolones and/or second-line injectables.
Based on available data, response rate (culture conversion at Week 120 endpoint) was similar in patients with ≥4-fold increases in bedaquiline MIC (5/12) and patients with <4-fold increases (3/7).
In the 40-week SIRTURO arm of Study 4, paired isolates (baseline and postbaseline, genotypically identical) susceptibility testing (MIC) results were available for 30 of 196 patients in the mITT population. At Week 132, three of five patients with a ≥4-fold increase in bedaquiline MIC and 25 of 25 patients with <4-fold increases had culture converted. Similarly, in the 28-week arm of Study 4, for 25 of 134 patients in the mITT population with paired isolates, two of four patients, with a ≥4-fold increase in bedaquiline MIC and 20 of 21 patients with <4-fold increases had culture converted. Based on the limited data, there was no clear relationship between bedaquiline MIC and microbiological outcomes.
For specific information regarding susceptibility test criteria and associated test methods and quality control standards recognized by FDA for this drug, please see:
www.fda.gov/STIC.
Pediatric Patients (12 years to less than 18 years of age)
Fifteen patients 14 years to less than 18 years of age were enrolled in the first cohort. The median age was 16 years, 80% were female, 53% were Black, 33% were White and 13% were Asian. No patient 12 years to less than 14 years of age was enrolled in this cohort. SIRTURO was administered as 400 mg once daily for the first two weeks and 200 mg three times per week for the following 22 weeks using the 100 mg tablet.
In the subset of patients with mycobacteria growth indicator tube (MGIT) culture positive pulmonary TB resistant to at least rifampin at baseline, treatment with SIRTURO resulted in conversion to a negative culture in 75% (6/8 patients) at Week 24, which was sustained at Week 120.
Pediatric Patients (5 years to less than 12 years of age)
Fifteen patients 5 years to 10 years of age were enrolled in the second cohort. The median age was seven years, 60% were female, 60% were Black, 33% were White and 7% were Asian. No patient older than 10 years to less than 12 years of age was enrolled in this cohort. The body weight range was 14 kg to 36 kg; only one patient weighing 14 kg was enrolled. SIRTURO was administered as 200 mg once daily for the first two weeks and 100 mg three times per week for the following 22 weeks using the 20 mg tablet.
In the subset of patients with MGIT culture positive pulmonary TB resistant to at least rifampin at baseline, treatment with SIRTURO resulted in conversion to a negative culture in 100% (3/3 patients) at Week 24, which was sustained at Week 120.
Pediatric Patients (2 years to less than 5 years of age)
Fifteen patients 2 years to less than 5 years of age were enrolled in the third cohort. The median age was 4 years, 47% were female, 27% were Black and 73% were Asian. At baseline, the body weight ranged from 10 kg to 16 kg. SIRTURO was administered as 8 mg/kg once daily for the first two weeks (dose range: 80 to 120 mg; not an approved dosing regimen) followed by 4 mg/kg three times per week (dose range: 40 to 60 mg; not an approved dosing regimen) for the following 22 weeks using the 20 mg tablet.
In the one patient with MGIT culture positive pulmonary TB resistant to at least rifampin at baseline, treatment with SIRTURO resulted in conversion to a negative culture (1/1 MGIT culture evaluable patient) at Week 24, which was sustained at Week 120.
SIRTURO 20 mg Tablet
Store in original container. Bottle contains desiccant. Do not discard desiccant. Protect from light and moisture. Keep the container tightly closed.
Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
SIRTURO 100 mg Tablet
Dispense in original container. Store tablets dispensed outside the original container in a tight light-resistant container with an expiration date not to exceed 3 months. Protect from light. Keep the container tightly closed.
Store at 25°C (77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Serious Adverse Reactions
Advise patients that the following serious side effects can occur with SIRTURO: heart rhythm abnormalities, death and/or hepatitis. In addition, advise patients about other potential side effects: nausea, vomiting, joint pain, increased transaminases, dizziness, headache, myalgia, diarrhea, increased blood amylase, hemoptysis, chest pain, anorexia, rash, and/or abdominal pain. Additional testing may be needed to monitor or reduce the likelihood of adverse effects.
Compliance with Treatment
Advise patients to take SIRTURO in combination with other antimycobacterial drugs as prescribed. Emphasize compliance with the full course of therapy. Advise patients that skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the treatment and (2) increase the likelihood that their mycobacterium may develop resistance and the disease will not be treatable by SIRTURO or other antimycobacterial drugs in the future.
If a dose is missed during the first 2 weeks of treatment, advise patients not to make up the missed dose but to continue the usual dosing schedule. From Week 3 onwards, if a dose is missed, advise patients to take the missed dose as soon as possible, and then resume the 3 times a week regimen.
Ensure that the total dose of SIRTURO during a 7-day period does not exceed the recommended weekly dose (with at least 24 hours between each intake).
Administration Instructions
Advise patients to take SIRTURO with food.
Advise patients who have difficulty swallowing tablets that SIRTURO 20 mg tablet can be administered by the following methods:
- Dispersed in water and the mixture administered immediately. To aid with administration, the dispersed mixture in water can be further mixed with a beverage (e.g., water, milk products, apple juice, orange juice, cranberry juice or carbonated beverage) or soft food (e.g., yogurt, apple sauce, mashed banana or porridge) and then administered immediately,
- Crushed and mixed with soft food and the mixture administered immediately,
- Administered through a feeding tube
[see
Dosage and Administration (2.6)]
.
Use with Alcohol and other Medications
Instruct patients to abstain from alcohol, hepatotoxic medications or herbal products.
Advise patients to discuss with their physician the other medications they are taking and other medical conditions before starting treatment with SIRTURO.
Lactation
Advise patients not to breastfeed during treatment with SIRTURO and for 27.5 months after the last dose unless infant formula is not available. If an infant is exposed to bedaquiline through breast milk, advise caregivers to monitor the infant for signs of bedaquiline-related adverse reactions, such as hepatotoxicity (yellowing of the eyes and changes in the color of the urine or stool)
[see
Adverse Reactions (6)and
Use in Specific Populations (8.2)]
.
Manufactured for:
Janssen Products, LP
Horsham, PA 19044, USA
For patent information: www.janssenpatents.com
©Johnson & Johnson and its affiliates 2012-2025